Biogen published key data about controversial Alzheimer’s drug Aduhelm in The Journal of the Prevention of Alzheimer’s Disease. Some experts expressed suspicion over the data being published in a low-impact journal. (STAT)

As part of the company’s larger push into cancer R&D, Sanofi is partnering with Seagen to fund three of its oncology candidates. The deal will bring together Sanofi’s antibodies with Seagan’s antibody drug conjugate technology. (Endpoints News)

The U.S., EU, South Africa and India have reached a compromise on an intellectual property rights waiver for COVID-19 vaccines. Under the terms of the agreement, low-income countries could use patented information to produce and supply COVID-19 vaccines without the consent of the patent holder. (Politico)

An uptick of global COVID-19 cases may signal new problems as many countries drop public health restrictions, according to the World Health Organization. “These increases are occurring despite reductions in testing in some countries, which means the cases we’re seeing are just the tip of the iceberg,” WHO Director-General Tedros Adhanom Ghebreyesus said. (Reuters)

Opening arguments in the trial of former Theranos president and COO Ramesh “Sunny” Balwani are scheduled to begin this week. Balwani faces fraud and conspiracy charges, with each charge carrying a penalty of up to 20 years in prison. (CNBC Weekly)